The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

Once its potential as a means of stimulating an immune response had been established ... only provide benefits if they can reach the living cells and be processed into protein.

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Formulating probiotics with stabilizers, employing encapsulation techniques ... composed of inactivated cells, provide similar benefits through their bioactive components. Both probiotics and ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Cells navigating in complex microenvironments frequently encounter narrow spaces that physically challenge migration.

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Battling a chronic disease is like running a marathon where T cells, the immune system’s frontline defenders, are the runners. When the starter’s pistol fires, the runners are fast and strong.